Development of sarcoidosis during etanercept therapy
| Autor: | Takashi Ishiguro, Yoshinori Kawabata, Yousuke Miyahara, Hiroo Saito, Kazuyoshi Kurashima, Koichiro Yoneda, Aya Matsushita, Mikio Ubukata, Shozaburo Yamaguchi, Noriko Tsuchiya, Noboru Takayanagi, Ryozo Yano, Keiji Harasawa, Tsutomu Yanagisawa, Yutaka Sugita, Daidou Tokunaga |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
musculoskeletal diseases
Pathology medicine.medical_specialty Mediastinal lymphadenopathy Arthritis Lung biopsy Receptors Tumor Necrosis Factor Etanercept Arthritis Rheumatoid Sarcoidosis Pulmonary Internal Medicine medicine Humans skin and connective tissue diseases Aged business.industry Tumor Necrosis Factor-alpha General Medicine medicine.disease Symptomatic relief Rheumatoid arthritis Antirheumatic Agents Immunoglobulin G Female Sarcoidosis business Tomography X-Ray Computed Epithelioid cell medicine.drug |
| Zdroj: | Internal medicine (Tokyo, Japan). 47(11) |
| ISSN: | 1349-7235 |
| Popis: | This report describes a 65-year-old woman who developed granulomatous lesions consistent with sarcoidosis during etanercept therapy for rheumatoid arthritis. Hilar and mediastinal lymphadenopathy and multiple nodules in both lung fields developed 21 months after administration of etanercept. Noncaseating epithelioid cell granulomas consistent with sarcoidosis were detected in a lung biopsy specimen and in the parietal pleura obtained via thoracotomy. Diseases showing similar histologic changes were excluded, and a diagnosis of sarcoidosis was made. Etanercept was discontinued, which resulted in symptomatic relief, improvement of oxygenation and radiologic findings. There is substantial evidence of tumor necrosis factor-alpha involvement in the induction and maintenance of granuloma formation; however, we should keep in mind that granulomatous disease, such as sarcoidosis, can develop during treatment with a tumor necrosis factor-alpha blocking agent, such as etanercept. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|